Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Exanthema × ruxolitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 36 Myeloproliferative Disorders 29 Polycythemia Vera 21 Leukemia, Myeloid, Acute 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Leukemia 15 Myelodysplastic Syndromes 13 Thrombocythemia, Essential 12 Multiple Myeloma 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Breast Neoplasms 8 Recurrence 7 Neoplasms 7 Myelodysplastic-Myeloproliferative Diseases 7 Leukemia, Myelomonocytic, Chronic 7 Graft vs Host Disease 7 Pancreatic Neoplasms 6 Hematologic Neoplasms 6 Prostatic Neoplasms 5 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Leukemia, Myeloid, Chronic-Phase 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Hodgkin Disease 5 Hematologic Diseases 5 Thrombocytosis 4 Carcinoma, Non-Small-Cell Lung 4 Bone Marrow Diseases 4 Triple Negative Breast Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Gels 2 Fulvestrant 2 Doxycycline 2 Dapsone 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Sirolimus 1 Provitamins 1 Prednisone 1 Panitumumab 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06399029 2025-11-19

TRUX-LST

University of Zurich

Phase 2 Recruiting

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡